Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Bisphosphonates for post-menopausal osteoporosis: are they all the same?

Rizzoli R.

QJM. 2011 Apr;104(4):281-300. doi: 10.1093/qjmed/hcq259. Epub 2011 Jan 21. Review.

PMID:
21258058
2.

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C.

Osteoporos Int. 2011 Feb;22(2):373-90. doi: 10.1007/s00198-010-1453-5. Epub 2010 Nov 18. Review.

3.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

PMID:
21060033
4.

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research..

J Bone Miner Res. 2010 Nov;25(11):2267-94. doi: 10.1002/jbmr.253. Erratum in: J Bone Miner Res. 2011 Aug;26(8):1987.

5.

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.

Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V.

BMJ. 2010 Sep 1;341:c4444. doi: 10.1136/bmj.c4444.

6.

Exposure to oral bisphosphonates and risk of esophageal cancer.

Cardwell CR, Abnet CC, Cantwell MM, Murray LJ.

JAMA. 2010 Aug 11;304(6):657-63. doi: 10.1001/jama.2010.1098.

7.

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

Ferrari-Lacraz S, Ferrari S.

Osteoporos Int. 2011 Feb;22(2):435-46. doi: 10.1007/s00198-010-1326-y. Epub 2010 Jun 23. Review. Erratum in: Osteoporos Int. 2011 Feb;22(2):739.

PMID:
20571772
8.

Adverse effects of bisphosphonates.

Abrahamsen B.

Calcif Tissue Int. 2010 Jun;86(6):421-35. doi: 10.1007/s00223-010-9364-1. Epub 2010 Apr 21. Review.

PMID:
20407762
9.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; Fracture Intervention Trial Steering Committee.; HORIZON Pivotal Fracture Trial Steering Committee..

N Engl J Med. 2010 May 13;362(19):1761-71. doi: 10.1056/NEJMoa1001086. Epub 2010 Mar 24.

10.

Denosumab-related osteonecrosis of the jaws.

Kyrgidis A, Toulis KA.

Osteoporos Int. 2011 Jan;22(1):369-70. doi: 10.1007/s00198-010-1177-6. Epub 2010 Mar 20. No abstract available.

PMID:
20306021
11.

Another selective estrogen-receptor modulator for osteoporosis.

Becker C.

N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847. No abstract available. Erratum in: N Engl J Med. 2010 Jul 22;363(4):398.

PMID:
20181977
12.

Lasofoxifene in postmenopausal women with osteoporosis.

Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; PEARL Study Investigators..

N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692. Erratum in: N Engl J Med. 2011 Jan 20;364(3):290. Kucu kdeveci A [corrected to Kucukdeveci, A].

13.

Long-term use of bisphosphonates in osteoporosis.

Watts NB, Diab DL.

J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Epub 2010 Feb 19. Review.

PMID:
20173017
14.

Osteonecrosis of the jaw and bisphosphonates.

Khan A.

BMJ. 2010 Feb 2;340:c246. doi: 10.1136/bmj.c246. No abstract available.

PMID:
20124367
15.

Atrial fibrillation and bisphosphonate therapy.

Pazianas M, Compston J, Huang CL.

J Bone Miner Res. 2010 Jan;25(1):2-10. doi: 10.1359/jbmr.091201. Review.

16.

Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab.

Toulis KA, Anastasilakis AD.

Osteoporos Int. 2010 Nov;21(11):1963-4. doi: 10.1007/s00198-009-1145-1. Epub 2009 Dec 15. No abstract available. Erratum in: Osteoporos Int. 2010 Nov;21(11):1965. A Toulis, K [corrected to Toulis, K A]; D Anastasilakis, A [corrected to Anastasilakis, A D].

PMID:
20012939
17.

Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity.

Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY.

Osteoporos Int. 2010 May;21(5):723-32. doi: 10.1007/s00198-009-1097-5. Epub 2009 Nov 17. Review.

PMID:
19921087
18.

Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.

Lewiecki EM.

J Womens Health (Larchmt). 2009 Oct;18(10):1615-26. doi: 10.1089/jwh.2008.1086. Review.

PMID:
19857095
19.

Osteonecrosis of the jaws induced by anti-RANK ligand therapy.

Taylor KH, Middlefell LS, Mizen KD.

Br J Oral Maxillofac Surg. 2010 Apr;48(3):221-3. doi: 10.1016/j.bjoms.2009.08.030.

PMID:
19836866
20.

Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.

Breart G, Cooper C, Meyer O, Speirs C, Deltour N, Reginster JY.

Osteoporos Int. 2010 Jul;21(7):1181-7. doi: 10.1007/s00198-009-1050-7. Epub 2009 Oct 6.

Supplemental Content

Support Center